Spatial Heterogeneity of the Hepatocellular Carcinoma Microenvironment Determines the Efficacy of Immunotherapy

Overview

Journal Discov Oncol

Publisher Springer

Specialty Oncology

Date 2025 Jan 8

PMID 39775241

Authors

Minni Zhang

Kailin Huang

Qiushi Yin

Xueqin Wu

Mingyue Zhu

Mengsen Li

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) remains a global health challenge owing to its widespread incidence and high mortality. HCC has a specific immune tolerance function because of its unique physiological structure, which limits the efficacy of chemotherapy, radiotherapy, and molecular targeting. In recent years, new immune approaches, including adoptive cell therapy, tumor vaccines, and oncolytic virus therapy, have shown great potential. As the efficacy of immunotherapy mainly depends on the spatial heterogeneity of the tumor immune microenvironment, it is necessary to elucidate the crosstalk between the composition of the liver cancer immune environment, from which potential therapeutic targets can be selected to provide more appropriate individualized treatment programs. The role of spatial heterogeneity of immune cells in the microenvironment of HCC in the progression and influence of immunotherapy on improving the treatment and prognosis of HCC were comprehensively analyzed, providing new inspiration for the subsequent clinical treatment of liver cancer.

References

Li L, Xu L, Yan J, Zhen Z, Ji Y, Liu C . CXCR2-CXCL1 axis is correlated with neutrophil infiltration and predicts a poor prognosis in hepatocellular carcinoma. J Exp Clin Cancer Res. 2015; 34:129. PMC: 4621872. DOI: 10.1186/s13046-015-0247-1. View

Nolan E, Lindeman G, Visvader J . Deciphering breast cancer: from biology to the clinic. Cell. 2023; 186(8):1708-1728. DOI: 10.1016/j.cell.2023.01.040. View

Wu J, Gao W, Tang Q, Yu Y, You W, Wu Z . M2 Macrophage-Derived Exosomes Facilitate HCC Metastasis by Transferring α β Integrin to Tumor Cells. Hepatology. 2020; 73(4):1365-1380. PMC: 8360085. DOI: 10.1002/hep.31432. View

Xiang X, Niu Y, Wang Z, Ye L, Peng W, Zhou Q . Cancer-associated fibroblasts: Vital suppressors of the immune response in the tumor microenvironment. Cytokine Growth Factor Rev. 2022; 67:35-48. DOI: 10.1016/j.cytogfr.2022.07.006. View

Batra S, Rathi P, Guo L, Courtney A, Fleurence J, Balzeau J . Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma. Cancer Immunol Res. 2020; 8(3):309-320. PMC: 10765595. DOI: 10.1158/2326-6066.CIR-19-0293. View

Pan Z, Di S, Shi B, Jiang H, Shi Z, Liu Y . Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1-CH3 fusion protein. Cancer Immunol Immunother. 2018; 67(10):1621-1634. PMC: 11028056. DOI: 10.1007/s00262-018-2221-1. View

Dembic Z, Haas W, Weiss S, McCubrey J, Kiefer H, von Boehmer H . Transfer of specificity by murine alpha and beta T-cell receptor genes. Nature. 1986; 320(6059):232-8. DOI: 10.1038/320232a0. View

Hinshaw D, Shevde L . The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019; 79(18):4557-4566. PMC: 6744958. DOI: 10.1158/0008-5472.CAN-18-3962. View

Ho D, Tsui Y, Chan L, Sze K, Zhang X, Cheu J . Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma. Nat Commun. 2021; 12(1):3684. PMC: 8211687. DOI: 10.1038/s41467-021-24010-1. View

10.

Zhang J, Wu N, Lian Z, Feng H, Jiang Q, Chen X . The Combined Antitumor Effects of I Radioactive Particle Implantation and Cytokine-Induced Killer Cell Therapy on Xenograft Hepatocellular Carcinoma in a Mouse Model. Technol Cancer Res Treat. 2018; 16(6):1083-1091. PMC: 5762075. DOI: 10.1177/1533034617732204. View

11.

Sun L, Guo H, Jiang R, Lu L, Liu T, He X . Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy in hepatocellular carcinoma. Tumour Biol. 2015; 37(1):799-806. DOI: 10.1007/s13277-015-3845-9. View

12.

Haider C, Hnat J, Wagner R, Huber H, Timelthaler G, Grubinger M . Transforming Growth Factor-β and Axl Induce CXCL5 and Neutrophil Recruitment in Hepatocellular Carcinoma. Hepatology. 2018; 69(1):222-236. PMC: 6590451. DOI: 10.1002/hep.30166. View

13.

Wu T, Zhang L, Zeng Z, Yan T, Cheng J, Miao X . Complete Response to PD-1 Inhibitor in Primary Hepatocellular Carcinoma Patients Post-Progression on Bi-Specific Antibody Conjugated CIK Cell Treatment: A Report of Two Cases. Onco Targets Ther. 2022; 14:5447-5453. PMC: 8702989. DOI: 10.2147/OTT.S333604. View

14.

Dong P, Ma L, Liu L, Zhao G, Zhang S, Dong L . CD86⁺/CD206⁺, Diametrically Polarized Tumor-Associated Macrophages, Predict Hepatocellular Carcinoma Patient Prognosis. Int J Mol Sci. 2016; 17(3):320. PMC: 4813183. DOI: 10.3390/ijms17030320. View

15.

Liu M, Zhou J, Liu X, Feng Y, Yang W, Wu F . Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma. Gut. 2019; 69(2):365-379. DOI: 10.1136/gutjnl-2018-317257. View

16.

Zhu A, Abbas A, Ruiz de Galarreta M, Guan Y, Lu S, Koeppen H . Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med. 2022; 28(8):1599-1611. DOI: 10.1038/s41591-022-01868-2. View

17.

Che G, Yin J, Wang W, Luo Y, Chen Y, Yu X . Circumventing drug resistance in gastric cancer: A spatial multi-omics exploration of chemo and immuno-therapeutic response dynamics. Drug Resist Updat. 2024; 74:101080. DOI: 10.1016/j.drup.2024.101080. View

18.

Li H . Intercellular crosstalk of liver sinusoidal endothelial cells in liver fibrosis, cirrhosis and hepatocellular carcinoma. Dig Liver Dis. 2021; 54(5):598-613. DOI: 10.1016/j.dld.2021.07.006. View

19.

Maskalenko N, Zhigarev D, Campbell K . Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders. Nat Rev Drug Discov. 2022; 21(8):559-577. PMC: 10019065. DOI: 10.1038/s41573-022-00413-7. View

20.

Titov A, Zmievskaya E, Ganeeva I, Valiullina A, Petukhov A, Rakhmatullina A . Adoptive Immunotherapy beyond CAR T-Cells. Cancers (Basel). 2021; 13(4). PMC: 7916861. DOI: 10.3390/cancers13040743. View